<article>Singapore’s sovereign fund <a href="http://www.dealstreetasia.com/?s=GIC">GIC</a> Thursday said it will invest HK$659 million ($85.03 million), and become a ‘key shareholder’ in <a style="color: #000080;" href="http://www.bloomagebio-tech.com/">Bloomage BioTechnology Corp</a>, a leading medical cosmetic products and services firm in China. </article>

Singapore’s sovereign fund <a href="http://www.dealstreetasia.com/?s=GIC">GIC</a> Thursday said it will invest HK$659 million ($85.03 million), and become a ‘key shareholder’ in <a style="color: #000080;" href="http://www.bloomagebio-tech.com/">Bloomage BioTechnology Corp</a>, a leading medical cosmetic products and services firm in China. 
The deal will see GIC invest HK$465 million in convertible bonds and HK$194 million in new shares, the Hong Kong-listed company. 
The conversion price for the convertible bonds is HK$17.2 per share at a coupon of 4 per cent, and the subscription price for new shares is HK$12.0 per share, the company&#8217;s statement added. The Singapore fund, which has assets of S$344 billion, according to the Sovereign Wealth Fund Institute, will hold approximately 4.84 per cent of the issued share capital in Bloomage BioTechnology. 
Bloomage BioTechnology said it will use the proceeds to continue with its internal organic growth and external acquisitive growth strategy to inject vitality into the aesthetic medical ecosystem in China and to drive its domestic and global expansion in the aesthetic medical sector. 
Jin Xuekun, the chief executive of Bloomage BioTech, said, “The investment shows GIC’s recognition on our track record and future potential as well as our strategy of building up aesthetic medical ecosystem in China, which not only provides the company with additional capital, but also further enhances the company’s global operation, improving the cash flow and keeping the leverage ratio at an appropriate level.&#8221;
Sharon Sun Xiaoning, chief representative of greater China and head of direct investments group (China), GIC Special Investments, said, As a disciplined, long-term value investor, GIC believes in the strong growth potential of China’s aesthetic medical sector.”
Also Read:
<a style="color: #ff0000;" title="Singapore: GIC to acquire Greenko Mauritius for $251m" href="http://www.dealstreetasia.com/stories/singapore-gic-to-buy-majority-stake-in-greenko-mauritius-for-251m-16347/" rel="bookmark">Singapore: GIC to acquire Greenko Mauritius for $251m</a>
<a style="color: #ff0000;" title="Singapore’s GIC &amp; Japan’s Mitsui interested in Glencore agriculture sale: Report" href="http://www.dealstreetasia.com/stories/singapores-gic-japans-mitsui-interested-in-glencore-agriculture-sale-report-14422/" rel="bookmark">Singapore’s GIC &amp; Japan’s Mitsui interested in Glencore agriculture sale: Report</a>
<a style="color: #ff0000;" title="Singapore: GIC forms JV with Macerich Company to invest in five US retail assets" href="http://www.dealstreetasia.com/stories/gic-forms-jv-with-macerich-company-to-invest-in-five-us-retail-assets-14273/" rel="bookmark">Singapore: GIC forms JV with Macerich Company to invest in five US retail assets</a>

Singapore’s sovereign fund GIC Thursday said it will invest HK$659 million ($85.03 million), and become a ‘key shareholder’ in Bloomage BioTechnology Corp

GIC invests $85m in China's Bloomage BioTechnology

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

GIC invests $85m in China's Bloomage BioTechnology

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief